Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 28, 2007
JNCI Journal of the National Cancer Institute 2007 99(17):1282-1289; doi:10.1093/jnci/djm149
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/17/1282    most recent
djm149v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savage, L.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

NCI Director Opts Against Breast Cancer Prevention Trial In Favor of Biomarkers

Liz Savage

The first 150 words of the full text of this article appear below.

A major breast cancer prevention trial has fallen victim to the squeeze of the National Cancer Institute's belt-tightening. NCI head John Niederhuber, M.D., decided in June that the institute would not fund the third clinical trial in a series of breast cancer prevention studies, even after it had been approved in an extensive review process.

The trial, known as STELLAR (Study to Evaluate Letrozole and Raloxifene), had been embroiled in controversy since Niederhuber put it on hold in January. His decision comes after months of closed-door discussions and an ad hoc review process, which proponents of the trial called arbitrary and capricious. Many in the cancer prevention community speculate that this ruling will shape the future of breast cancer prevention research. Whether it is for better or worse remains a matter of opinion.

"We’re surprised that the director chose to put a hold on this and develop a process outside . . . [Full Text of this Article]

Changing the Process

Pros and Cons

In Pursuit of Biomarkers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Raloxifene Prevails in STAR Trial, May Face Easier Road to Acceptance Than Previous Drugs
Brian Vastag
J Natl Cancer Inst 2006 98: 733-735. [Extract] [Full Text] [PDF]

Researchers Wonder Why High-Risk Women Are Not Taking Chemoprevention Drugs
Liz Savage
J Natl Cancer Inst 2007 99: 913-914. [Extract] [Full Text] [PDF]